Adaptive Biotechnologies announced that it has signed a biomarker discovery agreement facilitated by the Johnson & Johnson Innovation Centre in California. According to the agreement, Adaptive will use its patented immune profiling assay, immunoSEQTM, to allow an in-depth characterisation of the immune response to diseases being studied and select immunology and oncology drugs being developed by Janssen Research & Development LLC.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
156.6 USD | +3.69% |
|
+4.78% | -0.10% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.10% | 363B | |
+55.35% | 848B | |
+31.64% | 627B | |
+15.47% | 318B | |
+13.10% | 299B | |
+15.51% | 243B | |
+16.72% | 225B | |
+16.54% | 179B | |
+4.31% | 167B | |
+2.52% | 125B |
- Stock Market
- Equities
- JNJ Stock
- News Johnson & Johnson
- Adaptive Biotechnologies Signs Discovery Agreement with Johnson & Johnson Innovation Centre